Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 Statement of Cash Flows

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-07-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
Indivior Pharmaceuticals, Inc. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $97,000,000.00Net income → Operating adjustments reconciliation: $40,000,000.00Other current and noncurrent assets → Operating adjustments reconciliation: $15,000,000.00Stock-based compensation → Operating adjustments reconciliation: $8,000,000.00Impact from foreign exchange movements → Operating adjustments reconciliation: $3,000,000.00Depreciation and amortization → Operating adjustments reconciliation: $1,000,000.00Amortization of right-of-use assets → Operating adjustments reconciliation: $1,000,000.00Current inventories → Operating adjustments reconciliation: $1,000,000.00Operating adjustments reconciliation → Other current and noncurrent liabilities: $49,000,000.00Operating adjustments reconciliation → Deferred income taxes: $17,000,000.00Operating adjustments reconciliation → Accounts receivable: $2,000,000.00Operating adjustments reconciliation → Accrued legal and settlement expenses: $1,000,000.00Other → financing reconciliation: $1,000,000.00financing reconciliation → Remaining financing cash flows, net (calculated): $1,000,000.00Net cash used in investing activities → investing reconciliation: $14,000,000.00Sales and maturities of debt securities → investing reconciliation: $4,000,000.00investing reconciliation → Purchases of property and equipment: $14,000,000.00investing reconciliation → Purchases of investments in debt securities: $4,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $222,000,000.00Net cash from operating activities → Cash sources and uses: $97,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $305,000,000.00Cash sources and uses → Net cash used in investing activities: $14,000,000.00Net income: $137,000,000.00Net income+$137.00 MDepreciation and amortization: $1,000,000.00Depreciation & amortization+$1.00 MAmortization of right-of-use assets: $1,000,000.00Operating lease amortization+$1.00 MStock-based compensation: $8,000,000.00Stock-based compensation+$8.00 MImpairment of tangible and intangible assets: $0.00Loss on debt extinguishment: $0.00Unrealized loss on equity investments: $0.00Deferred income taxes: -$17,000,000.00Deferred income taxes−$17.00 MImpact from foreign exchange movements: $3,000,000.00FX transaction gain & loss+$3.00 MAmortization of debt issuance costs: $0.00Other adjustments, net: $0.00Accounts receivable: -$2,000,000.00Accounts receivable−$2.00 MCurrent inventories: $1,000,000.00Inventories+$1.00 MOther current and noncurrent assets: $15,000,000.00Other operating assets+$15.00 MAccrued legal and settlement expenses: -$1,000,000.00Accrued legal and settlement expenses−$1.00 MOther current and noncurrent liabilities: -$49,000,000.00Other operating liabilities−$49.00 MNet cash from operating activities: $97,000,000.00Operating cash+$97.00 MOperating adjustments reconciliation: $69,000,000.00Proceeds from the issuance of common stock: $0.00Cash paid for repurchases of common stock: -$0.00Proceeds from debt, net: $0.00Repayments of debt: -$0.00Other: $1,000,000.00Other financing, net+$1.00 MTransaction costs related to debt refinancing: -$0.00Settlement of equity awards: -$0.00Remaining financing cash flows, net (calculated): -$1,000,000.00Remaining financing (calculated)−$1.00 MNet cash from financing activities: $0.00Financing cash$0.00financing reconciliation: $1,000,000.00Purchases of property and equipment: -$14,000,000.00PP&E purchases−$14.00 MPurchases of in-process research and development and intangible assets: $0.00Purchases of investments in debt securities: -$4,000,000.00HTM securities purchases−$4.00 MSales and maturities of debt securities: $4,000,000.00HTM sales & maturities+$4.00 MNet cash used in investing activities: -$14,000,000.00. Cash required to fund net payments.Investing cash−$14.00 Minvesting reconciliation: $18,000,000.00Cash sources and uses: $319,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $222,000,000.00Beginning cash$222.00 MEnding cash: Cash, cash equivalents, and restricted cash: $305,000,000.00Ending cash$305.00 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$83.00 MOperating cash − cash spent on PP&ECash flow / Net income0.71×Operating cash flow ÷ net incomeNet cash change+$83.00 MEnding cash − beginning cash
Chart details

Indivior Pharmaceuticals, Inc. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026

Cash flows for Jul 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Jun 30, 2026. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2026
222,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
97,000,000 US dollars. Net cash provided.
Net income
137,000,000 US dollars
Depreciation and amortization
1,000,000 US dollars
Amortization of right-of-use assets
1,000,000 US dollars
Stock-based compensation
8,000,000 US dollars
Impairment of tangible and intangible assets
0 US dollars
Loss on debt extinguishment
0 US dollars
Unrealized loss on equity investments
0 US dollars
Deferred income taxes
negative 17,000,000 US dollars
Impact from foreign exchange movements
3,000,000 US dollars
Amortization of debt issuance costs
0 US dollars
Other adjustments, net
0 US dollars
Accounts receivable
negative 2,000,000 US dollars
Current inventories
1,000,000 US dollars
Other current and noncurrent assets
15,000,000 US dollars
Accrued legal and settlement expenses
negative 1,000,000 US dollars
Other current and noncurrent liabilities
negative 49,000,000 US dollars
Investing activities
negative 14,000,000 US dollars. Net cash used.
Purchases of property and equipment
negative 14,000,000 US dollars
Purchases of in-process research and development and intangible assets
0 US dollars
Purchases of investments in debt securities
negative 4,000,000 US dollars
Sales and maturities of debt securities
4,000,000 US dollars
Financing activities
0 US dollars. No net cash provided or used. The remaining amount is calculated by subtracting the other displayed items from the financing total. This quarter is the year to date less the prior quarter's year to date, and the prior quarter's tagged financing lines do not add up to its total. It may combine inflows and outflows.
Proceeds from the issuance of common stock
0 US dollars
Cash paid for repurchases of common stock
0 US dollars
Proceeds from debt, net
0 US dollars
Repayments of debt
0 US dollars
Other
1,000,000 US dollars
Transaction costs related to debt refinancing
0 US dollars
Settlement of equity awards
0 US dollars
Remaining financing cash flows, net (calculated)
negative 1,000,000 US dollars
Operating adjustment reconciliation
69,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing displayed reconciliation
1,000,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
investing gross reconciliation
18,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Sep 30, 2026
305,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
319,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
83,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.71×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
97,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
14,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
83,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $97.00M of net income directly to operating cash and $40.00M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • The filer's reported cash figures differ by $1.00 M: its operating, investing and financing totals, its reported net change in cash and the move from its beginning to its ending cash do not all agree. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 97,000,000 US dollars minus 14,000,000 US dollars equals 83,000,000 US dollars.
  • The filer's reported cash figures differ by $1.00 M: its operating, investing and financing totals, its reported net change in cash and the move from its beginning to its ending cash do not all agree. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!